Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003082 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00003082: Completed Phase 1 study, sponsored by University of Arizona.
NCT00003082 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003082, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibodies in treating patients who have advanced cancer.
Interventions
- BIOLOGICAL monoclonal antibody A27.15
- BIOLOGICAL monoclonal antibody E2.3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-02 |
| Phase | Phase 1 |
What the finished NCT00003082 record still lists
NCT00003082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which monoclonal antibody A27.15 is the first listed.
NCT00003082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003082 about?
NCT00003082 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibodies in treating patients who have advanced cancer.
What is the current status of trial NCT00003082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 1997-12. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00003082?
The interventions under investigation include: monoclonal antibody A27.15 (BIOLOGICAL), monoclonal antibody E2.3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003082?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003082's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia